ERBB2 and breast cancer: At present, the Post Operative Therapy with Endocrine and TS-1 (POTENT) trial, a randomized, controlled, phase III study of postoperative chemotherapy in patients with ER-positive, HER2-negative breast cancer, is ongoing.